# An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children

> **NCT01439360** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 12046 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Quadrivalent seasonal influenza vaccine(Flu D-QIV) GSK2321138A
- **BIOLOGICAL:** Havrix Junior
- **BIOLOGICAL:** Prevenar 13
- **BIOLOGICAL:** Varivax/ProVarivax
- **BIOLOGICAL:** Varilrix

## Key facts

- **NCT ID:** NCT01439360
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10-01
- **Primary completion:** 2014-10-31
- **Final completion:** 2014-12-31
- **Target enrollment:** 12046 (ACTUAL)
- **Last updated:** 2018-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01439360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01439360, "An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01439360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*